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1. INTRODUCTION 
 
1.1. CORONARY ARTERY DISEASE 
 
Coronary artery disease (CAD) also called coronary heart disease (CHD) or 
ischemic heart disease (IHD) is caused by the obstruction of one or more 
coronary arteries resulting from the accumulation of atheromatous plaques 
within the walls of the coronary arteries. It is the leading cause of death 
worldwide accounting for 7.025 million deaths yearly or 12.9 per cent of total 
deaths (116) and the mortality is projected to rise to 7.594 million deaths or 
13.2% of deaths by 2015 and 9.245 million deaths or 13.2% by 2030 (117). In 
Europe ischemic heart disease is the leading cause of death with 2.245 million 
deaths or 24.8% of all deaths in 2011 (116). Nevertheless, ischemic heart 
disease does not consist a problem only when it has a fatal outcome. It is also 
one of the leading causes of burden of disease in the world. IHD accounted for 
159.659.000 disability-adjusted life years (DALYs) or 5.8% of total DALYs in 
2011. This data puts IHD on the 2nd place of leading causes of morbidity after 
lower respiratory infections with increasing tendency in the last decade (114). 
 
The manifestation of CAD was first clinically described based on the angina 
symptoms classified by Herberden in 1772 (156). Since then there has been 
extended research focused on the pathophysiological mechanisms that lead to 
CAD. The clinical manifestations of CAD include silent ischemia, stable angina 
pectoris, unstable angina pectoris (UA), myocardial infarction (MI), heart failure, 
and sudden cardiac death. 
 
Traditional risk factors for CAD include smoking (102, 145), obesity (121), 
dyslipidemia, arterial hypertension, diabetes and chronic kidney disease. Thus 
lifestyle modifications are suggested in CAD patients such as smoking 
cessation that is associated with a 36% mortality reduction in the post MI phase 
(37), adoption of a healthy diet such as “Mediterranean” diet (52), weight 
management (121) and physical activity.  
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At the same time pharmacological management plays an important role in relief 
from symptoms and prevention of cardiovascular events. For the symptomatic 
treatment of angina short acting nitrates, β-blockers or calcium channel 
blockers, ranolazin and ivabradine are indicated. For prevention of 
thromboischemic events a low-dose aspirin daily is recommended in all CAD 
patients with clopidogrel as an alternative in case of aspirin intolerance. Statins 
are recommended for all CAD patients and angiotensin converting enzyme 
inhibitors or Angiotensin II receptor blockers are recommended in the presence 
of comorbidities such as heart failure, diabetes or hypertension (143). 
 
When evaluating a patient with chronic coronary artery disease, doctors must 
choose their strategy between catheterization with revascularization, if feasible, 
combined with drug therapy or initial medical management with 
revascularization only if drug therapy fails. Although the superiority of coronary 
revascularization in relieving angina has been a consistent finding in many 
trials, only patients with high-risk profiles have been shown to benefit by 
reducing rates of subsequent myocardial infarction and (20, 44, 80, 162). 
Diabetics though present a high-risk group even when only mild symptoms are 
manifest. But trials in this group have also been controversial regarding major 
adverse cardiac events (MACE). The largest trial in the diabetic population 
showed that either therapeutic decision is correct in the setting of stable CAD 
(40). Latest trials have focused on which of the invasive options are most 
beneficial for diabetics with multivessel coronary artery disease, without 
reaching a unanimous verdict (55, 151). 
 
In patients with ACS, guidelines are clearer with an invasive treatment 
recommended for all patients without contraindications for revascularization. In 
STEMI patients the revascularization should be prompt, whereas in UA and 
NSTEMI patients without recurrent ischemia in the first 24 hours the invasive 
risk stratification can be reserved for a later time point, depending on their 
cumulative risk (e.g. calculated by the GRACE-score) between 2 and 72 hours 
(72, 143, 144).  
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1.2. DIABETES MELLITUS AND CARDIOVASCULAR DISEASE (CVD) 
 
Data from multiple epidemiological studies show that diabetes mellitus type 2 
(T2DM) is a major risk factor contributing to the development of all 
manifestations of cardiovascular disease, including fatal and non-fatal 
myocardial infarction and heart failure (5). Recent data support an increasing 
burden of cardiovascular disease attributable to diabetes mellitus (61). Along 
with the globally increasing prevalence of obesity and the aging population, the 
incidence and prevalence of T2DM is anticipated to rise. From the year 2000 to 
2030 increase of the prevalence of T2DM is projected to 100%, with those older 
than 65 years of age contributing the biggest share (155). CVD and 
cardiovascular events are major contributors to morbidity and mortality of 
diabetics, with estimations holding CVD responsible for at least 50% of all 
deaths in T2DM patients (15, 24, 38, 69, 115, 124). 
 
In the Norfolk cohort of European Prospective Investigation Into Cancer and 
Nutrition (EPIC-Norfolk) trial an increase of 1% in glycated hemoglobin (HbA1c) 
was associated with a 40% increase in CVD mortality in T2DM patients and with 
a 28% increase in risk of death independent of age, blood pressure, serum 
cholesterol, body mass index, and cigarette smoking habit (87). A meta-analysis 
of almost 700.000 subjects from 102 different prospective studies reported that 
diabetics presented with a near 2-fold increase in CVD risk, independent from 
other known CVD risk factors (50). Intensive glycemic control and its impact on 
CV outcomes has been a controversial subject for at least 2 decades (67). 
Therefore it is clear that metabolic control is essential in treating diabetics with 
CVD.  
 
A goal HbA1c of less than 7.0% has been proposed by the American Diabetes 
Association (ADA) and the European Association for the Study of Diabetes 
(EASD) for most of T2DM patients (81). The same position paper advises 
towards less stringent goals for patients with a history of severe hypoglycemia, 
limited life expectancy, advanced microvascular or macrovascular disease, or 
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those with long-standing diabetes (13). It has also been suggested that insulin 
may be atherogenic in a dose dependent fashion (42).  
 
CVD risk in T2DM patients most likely owes a multifactorial etiology. In T2DM 
patients there is often a clustering of additional CV risk factors closely 
associated with insulin resistance, including hypertension and central obesity 
(2, 41, 112). 
 
 
Figure 1.1 Glycemic continuum and cardiovascular disease.  
Diabetes mellitus type 2 is a state of combined IR, compensatory 
hyperinsulinemia and elevated PG, which lead to a higher cardiovascular risk 
and rapid development of macrovascular disease prior to diagnosis of diabetes 
(13). 
 
1.3. ATHEROSCLEROSIS AND MANIFESTATIONS OF CAD 
 
Epicardial coronary arteries are a major site of clinically relevant atherosclerotic 
disease (91, 129). Atherosclerosis is a chronic, systemic, lipid-associated, 
immuno-inflammatory disease of the medium and large-sized arteries resulting 
in plaque development. Plaques are principally formed at predilection sites that 
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are characterized by high endothelial stress (32). Atherosclerosis begins with 
our birth and the lesions develop over the course of our live, one of the longest 
incubation periods among human diseases. Despite the chronic character of the 
disease, its most dangerous effects occur suddenly. CAD includes two 
pathophysiological pathways that determine the clinical manifestations of the 
disease. One chronic, non-reversible process of progressive stenosis of the 
lumen of the coronary arteries and a very dynamic but potentially reversible 
process that leads to a hemodynamically significant occlusion of the coronary 
artery (131). 
 
Most plaques stay asymptomatic, some become obstructive leading to stable 
angina and a few are prone to thrombosis and disruption (vulnerable). When 
the progression of atherosclerosis has led to a high-grade stenosis, a platelet 
thrombus can occlude the vessel completely and cause ST-segment elevation 
myocardial infarction. When only incomplete or transient obstruction of flow 
occurs, the result is an acute coronary syndrome without persisting ST-segment 
elevation. In the complex process of plaque vulnerability and disruption 
inflammation plays an important pathophysiological role. Rarely, ACS may have 
a non-atherosclerotic etiology, e.g. thoracic trauma, dissection of arteries, 
thromboembolism, cocaine abuse or iatrogenic. 
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Figure 1.2: Development of atherosclerosis and possible progression to 
thrombosis and corresponding clinical events (131). 
 
1.3.1. ENDOTHELIAL DYSFUNCTION, VASCULAR INFLAMMATION: THE 
VALNURABLE PLAQUE THEORY 
 
According to the prevalent theory sudden and unpredictable changes in 
symptoms of atherosclerosis appear to be associated with plaque disruption. 
Genesis of ACS is the plaque rupture and not every plaque poses the same 
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danger of rupture. Patients with unstable angina or NSTEMI often enough have 
multiple plaques vulnerable to disruption (6, 68). 
 
Pathological studies in humans showed that thrombotic coronary occlusion after 
rupture of a lipid-rich atheroma seems to be the trigger for myocardial infarction 
in 73% of the cases (54, 56, 57). 
 
One of the seminal clinical studies outlining this is the collaborating PROSPECT 
Trial, in which Stone and colleagues investigated 697 patients undergoing 
elective PCI and systematic interventional imaging of the entire coronary artery 
tree using intravascular ultrasound (IVUS) to try to characterize the risk that 
individual lesion characteristics at baseline conferred regarding the recurrence 
of coronary events. This study identified three characteristics associated with 
plaque vulnerability: 
 
1. High plaque burden >70% (hazard ratio (HR) 5.03) 
2. Small minimal lumen area (<4 mm2, HR 3.21) 
3. Classification as a thin-cap fibroatheroma (HR 3.35) (139) 
 
The notion that cells mostly associated with the inflammatory response play an 
important role in the pathogenesis of ACS found fertile ground in the scientific 
community (74, 92). Currently it’s a common ground that the activation of 
inflammatory cells in the culprit lesion triggers the coronary plaque instability 
(73, 92). With imaging techniques available today investigation of arterial wall 
inflammation is indirectly possible e.g. by using FDG-PET (60).  
 
The dysfunctional endothelium cannot properly regulate the recruitment of 
leukocytes. Macrophage foam cells serve as lipid reserve and also induce 
decreased production of nitric oxide, aggravate the endothelial dysfunction 
(163) and lead to thickening of the intima media (59). They also serve as a 
source of pro-inflammatory mediators, such as cytokines and chemokines, 
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reactive oxygen intermediates or platelet activating factor that lead to a 
prolonged inflammatory activation of the endothelium (66). 
 
This type of antigen-stimulation independent amplified inflammatory response is 
described as innate immunity. Proliferation of smooth muscle cells (SMCs) 
furthers promotes atherosclerosis. Extracellular matrix makes up most of the 
volume of an atherosclerotic plaque in advanced stages. The imbalance in its 
production lies with the disrupted breakdown, which is catalyzed in part by 
matrix metalloproteinases (MMPs).  
 
The fibrous cap is a dynamic structure undergoing active remodeling. With its 
high concentration of type I collagen it can resist high amounts of stress. The 
collagen de novo synthesis is modulated by growth factors and supported by 
degradation through proteases produced from activated macrophages. The 
local apoptosis of SMCs on the cap tissue can also contribute to rupture (142). 
 
The lipid-rich core of the fibroatheroma when exposed after plaque rupture is 
highly thrombogenic and the thrombosis can lead to total or subtotal occlusion 
of the artery that cannot be compensated for through positive remodeling. This 
thrombus can fragment into smaller pieces, creating emboli that may cause 
necrosis in the area of the myocardium supplied by the culprit vessel (39, 53). 
 
1.3.2. MECHANISMS THAT CONTRIBUTE TO THE INCREMENTAL RISK 
FOR CAD IN DIABETICS 
 
The atheroma in type 2 diabetics is more prone to inflammation, thrombosis and 
has a higher lipid concentration than that of non-diabetics.  T2DM patients are 
obese (78) and adipose tissue at a hyperglycemic state intensively accumulates 
macrophages, that form foam cells and promote atherosclerosis through 
oxidized low-lipoprotein (LDL) scavenger receptor B (SR-B) and releases 
substances that further impair insulin sensitivity (128). At the same time 
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endothelial dysfunction and vascular remodeling is promoted involving 
overproduction of reactive oxygen species (ROS) (13, 36). 
 
The free fatty acids (FFA) induce increased production of very low-density 
lipoprotein (VLDL), which is more susceptible to oxidative stress (119, 164). At 
the same time the function of high-density lipoprotein (HDL) as protective factor 
is lost in diabetics (8, 62, 90). 
 
T2DM is a prothrombotic state with hypofybrinolytic abnormalities (70) and 
hyper-reactive, dysfunctional platelets. Hyperglycemia-induced up-regulation of 
platelet glycoproteins (Ib and IIb/IIIa), P-selectin and enhanced P2Y12 signaling 
are associated with the atherothrombotic risk in diabetics. Furthermore, the 
cardiovascular risk burden in T2DM is not diminished by intensive glycemic 
control and mechanism-based therapeutic strategies are needed such as 
inhibition of key-enzymes involved in protein-production and activation of 
pathways. There is also need for biomarkers aiding in early detection of CAD in 
asymptomatic patients and prediction of CV risk (13). 
 
 
 
 
 
Figure 1.3: Interaction of the pathophysiological mechanisms in diabetes and 
the resulting atherothrombotic risk. 
More than 90% of people withT2DM are obese and the release of free fatty 
acids (FFAs) and cytokines from adipose tissue directly impairs insulin 
sensitivity. The picture presents the interaction of the pathophysiological 
mechanisms in diabetes and the resulting atherothrombotic risk. Connecting 
arrows depict the mediators of such interactions.  
AGE = advanced glycated-products; FFA = free fatty acids; GLUT-4 = glucose 
transporter 4; HDL-C = high-density lipoprotein cholesterol; LDL = low-density 
lipoprotein particles; NO = nitric oxide; PAI-1 = plasminogen activator inhibitor-
1; PKC = protein kinase C; PPARy = peroxisome proliferator-activated receptor 
y; PI3K = phosphatidylinositide 3-kinase; RAGE = AGE receptor; ROS = 
reactive oxygen species; SR-B = scavenger receptor B; tPA = tissue 
plasminogen activator (13). 
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1.4. BIOMARKERS IN ACS 
 
1.4.1. HIGH-SENSITIVITY C-REACTIVE PROTEIN 
 
The acute-phase reactant CRP has emerged as a predictor for long-term events 
in ACS (125). CRP belongs to the superfamily of pentraxins and more 
specifically to the classic short pentraxins. It is a secreted endogenous PRM 
(pattern recognition molecule) and is synthesized by the liver (64). Limited 
number of germline-encoded PRMs are used by the innate immune system to 
detect conserved molecular structures known as pathogen-associated 
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molecular patterns (PAMPs) exposed on pathogens but absent from healthy 
host cells (82, 120, 123). 
 
In humans, CRP is a major acute-phase plasma protein, in which the serum 
concentration can rapidly increase in response to infection or tissue injury. It is 
the principal downstream mediator of the acute phase response and is primarily 
derived via IL-6- dependent hepatic biosynthesis. During the acute phase 
response, levels of CRP will increase within 2 hours of acute insult, reaching a 
peak at 48 hours and start declining relatively rapidly with a half-life of 18 hours. 
 
CRP levels can increase as a response to a wide variety of biological insults, 
infections, autoimmune inflammatory conditions or malignant processes. While 
CRP has multiple pro-inflammatory and proatherogenic properties, recent 
studies, one using a mendelian randomization approach (30) and a large 
genomics study (49), both reached the conclusion that C-reactive protein does 
not seem to be the cause of coronary heart disease, although it is a risk marker 
for it (49, 146). Various medications have been proved to reduce serum CRP 
levels, e.g. aspirin and clopidogrel or statins and that in turn reduce the 
incidence of major cardiovascular events (83, 127). 
 
After Liuzzo’s et al. first report on the prognostic role of CRP in acute coronary 
syndromes (94), several trials and meta-analysis have put that finding in clinical 
context (49) and now serum CRP levels are used in scores to determine one-
year mortality and the 10-year cardiovascular risk (122, 126, 157). The 
American Heart Association and the American College of Cardiology gave a 
recommendation for testing of CRP in asymptomatic intermediate-risk men 50 
years of age or younger or women 60 years of age or younger as a tool for CV 
risk assessment (Level of Evidence: B) (71). Elevation of CRP-levels is not only 
a predictor for CV-events, but also for the onset of T2DM. This might be 
because CRP correlates with characteristics of the metabolic syndrome, 
including insulin sensitivity, endothelial dysfunction, and hypofibrinolysis, as 
noted earlier. 
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Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study 
showed no association of CRP levels with P2Y12 inhibition and diminished 
levels of CRP 30days after the event (161). The concept of use of statins to 
reduce the CV-risk in patients with elevated hs-CRP independent from LDL-
Cholesterol levels has been confirmed in the A-to-Z clinical trial (107) and the 
JUPITER trial (127). 
 
 
1.4.2. MACROPHAGE MIGRATION INHIBITORY FACTOR 
 
Macrophage migration inhibitory factor (MIF or MMIF) also known as 
glycosylation-inhibiting factor (GIF), L-dopachromeisomerase/tautomerase, or 
phenylpyruvatetautomerase is a very pleiotropic and widely studied 
inflammatory cytokine, an evolutionarily highly conserved molecule with an 
almost ubiquitous expression pattern and an extensive regulatory activity in 
humans. MIF was first isolated back in the 60’s, as a protein from the 
supernatant of activated lymphocytes, however little was then known about its 
role. More light in its function was shed after the introduction of molecular 
biology. More specifically, MIF was categorized as a chemokine like factor in 
humans (43). 
 
MIF is expressed on the endothelium and macrophages and in humans it is 
involved in the innate immune response to bacterial pathogens and its 
expression at sites of inflammation suggests a role as mediator in regulating the 
function of macrophages in host defense. MIF counteracts the anti-inflammatory 
activity of glucocorticoids. Serum levels of MIF are elevated in patients with 
severe sepsis or septic shock and high levels of MIF are correlated with poor 
survival and drugs that inhibit tautomerase activity attenuate the risk of death 
due to sepsis (17, 18, 26, 27, 47, 51, 89, 104, 154). Data is widely available on 
the functions of this versatile molecule including its role in glomerulonephritis 
(159) and arthritis (16).  
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Regarding cardiovascular diseases, the expression and activity of MIF was 
recorded in the onset of atherogenesis and advanced lesions of 
hypercholesterolemic rabbits and humans (93). MIF is an inflammatory cytokine 
with a chemokine-like function, promoting leukocyte recruitment, adhesion and 
atherosclerotic lesion formation via the chemokine receptors CXCR2 und 
CXCR4 (23). It has also been shown that MIF deficiency considerably reduces 
atherogenesis in LDLr-/- (118), but no data is available on serum levels of MIF 
in CVD. Despite its wide tissue distribution, the secretion of MIF is tightly 
regulated, with triggers such as hypoxia/ischemia or oxidized low-density 
lipoprotein (9). Schmeisser et al. showed that MIF is expressed by advanced 
plaques and mainly in areas of enhanced instability (132); nevertheless the 
current studies are in dispute regarding how MIF affects the plaque size and 
stability of the vulnerable plaque (22, 134). 
 
Latest studies have shown a correlation of levels of MIF with cardiac 
dysfunction in diabetic patients (97, 160). In a known background of elevated 
MIF levels in diabetics and the correlation of MIF with the progression of 
glucose resistance to diabetes (88, 150, 152) the MONICA/KORA Augsburg 
Case-Cohort Study tried to include multiple inflammation-related biomarkers 
into a basic risk assessment model for cardiovascular events in type 2 diabetics 
(75). 
 
Pilot studies of our group demonstrated correlation of MIF levels with 
established inflammatory markers, the extent of cardiac necrosis marker 
release after PCI and ACS (110). 
 
1.4.3. GREMLIN-1 
 
Gremlin-1 is a secreted, highly conserved glycoprotein with an atomic mass of 
20.7 kDa and a structure shared by members of the TGF-β superfamily and 
Vascular Endothelial Growth Factors (106, 148, 149). Gremlin-1 plays a part 
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during lung, limb, urethra and kidney formation and neural crest cell 
differentiation through regulation of BMPs (33, 96, 103, 135, 140). Through its 
interaction with Slit proteins Gremlin-1 functions as an inhibitor of monocyte 
chemotaxis and through binding of VEGFR-2 acts as a proangiogenic agonist 
with a role in vascular development, angiogenesis-dependent diseases, and 
tumor neovascularization (106). 
 
Gremlin-1 is expressed in endothelial cells that are exposed to disturbed flow in 
mice aortas as well as in human coronary arteries (31, 45). An up-regulation of 
Gremlin-1 in pericytes in response to elevated glucose levels was reposted, 
suggesting a role in diabetic retinopathy (85). Additionally, a role in 
tubulointerstitial fibrosis in diabetic nephropathy has been suggested (46). 
 
In studies of our group we could demonstrate that Gremlin-1 regulates foam cell 
formation in vitro, is an endogenous antagonist of MIF and binds with high 
affinity to MIF. Administration of a dimeric recombinant fusion protein mGremlin-
1-Fc reduced the content of macrophages in atherosclerotic plaques, and limits 
atheroprogression and lesion instability (109). One can speculate that GREM1 
plays a pivotal role in proliferation of atherosclerotic lesions and plaque 
vulnerability and consequently instability. 
 
Pilot studies of our group in patients with ACS suggest a potential role of 
Grem1/MIF ratio to indicate acuity of CAD and the grade of plaque stability 
(108). 
 
 
 
1.5. SCOPE OF THE INVESTIGATION 
 
In this study we aimed to evaluate the expression of MIF and GREM1 in 
patients with symptomatic IHD with major focus in diabetics with CAD. 
Following research questions were pursued: 
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1. Are MIF and GREM1 expressed from human platelets, and if yes at what 
degree? 
2. Is the expression of MIF and GREM1 from human platelets dependent 
from platelet count, platelet activation or platelet aggregation? 
3. Is there a correlation between MIF and GREM1 levels in human platelets 
4. Do patients with stable ischemic heart disease express MIF and GREM1 
at the same degree as patients with acute coronary syndromes? 
5. Do diabetics with symptomatic ischemic heart disease have the same 
MIF and GREM1 platelet levels compared to non-diabetics? 
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2. METHODS 
 
2.1. STUDY DESIGN 
 
The study was conducted at the UniversitätsklinikumTübingen, Medizinische 
Universitätsklinik, Department für Innere Medizin III, Kardiologie und 
Kreislauferkrankungen. The institutional review board approved the study 
(270/2011BO1). 
 
2.2. STUDY PATIENTS AND PROTOCOLS 
 
Patients with stable CAD or acute coronary syndromes were enrolled at the 
time of percutaneous coronary intervention (PCI). The inclusion and exclusion 
criteria are as listed in Table 2.1. ACS Patients that did not undergo an 
intervention, either because of ACS without significant coronary stenosis or 
because they were referred for coronary artery bypass surgery (CABG) or 
because they were considered too frail/critical for intervention were not included 
in this study. All patients provided written informed consent. The study was 
approved by the institution ethics committee (270/2011BO1) ad complies with 
the declaration of Helsinki and the good clinical practice guidelines (1, 3, 4).   
 
Table 2.1: Inclusion and exclusion criteria in our study 
 
Clinical inclusion criteria 
 
1. Age ≥18 years  
 
2. Symptomatic CAD undergoing PCI 
 
3. Patient provides written, informed consent. 
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Clinical exclusion criteria 
 
1. Pregnant or nursing patients 
 
 
Angiographic inclusion criteria 
 
1. Lesions in at least 1 epicardial coronary artery requiring reperfusion 
therapy. 
2. Successful PCI of at least one lesion. 
 
Levels of serum creatinine, fasting lipids, glucose, glycated hemoglobin, and C-
reactive protein were measured at baseline. Blood was collected in EDTA tubes 
at the time of angiography, centrifuged at room temperature (1500xg) for 15 min 
and the supernatants were stored as EDTA-plasma at -80°C for the ELISA. At 
the same time citrate phosphate dextrose adenine (CPDA)-tubes were collected 
for the fluorescence-activated cell sorting (FACS). 1.5 mL blood was collected 
in hirudin tubes for Multiplate measurements of agonist induced platelet 
aggregation. 
 
 
2.3. CRITERIA FOR ACUTE MYOCARDIAL INFARCTION 
 
Acute myocardial infarction was defined according to the third universal 
definition (147). Detection of a rise and/or fall of cardiac troponin with at least 
one value above the 99th percentile URL and with at least one of the following: 
(i) symptoms of ischemia, or (ii) new or presumed new significant ST-segment–
T wave (ST–T) changes or new left bundle branch block, or (iii) development of 
pathological Q waves in the electrocardiogram, or (iv) imaging evidence of new 
loss of viable myocardium or new regional wall motion abnormality, or (v) 
identification of an intracoronary thrombus by angiography or autopsy according 
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to the third universal definition of myocardial infarction. In our laboratory the cut-
off value for troponin I was 0.04 μg/l. 
 
 
2.4. DEFINITION OF DIABETES MELLITUS TYPE 2 
 
Diabetes mellitus type 2 was defined according to current diagnostic criteria of 
the American Diabetes Association (ADA) (7) and the world health organization 
(WHO) (113) as the following:  
 
Table 2.2: Major Diagnostic Criteria for Diabetes and Prediabetic or At-Risk States 
Measure  
American Diabetes 
Association World Health Organization 
 
Diabetes Prediabetes Diabetes 
Impaired Glucose 
Regulation 
Fasting plasma 
glucose ≥126 mg/dl 
100–125 mg/dl 
(IFG) ≥126 mg/dl 110–125 mg/dl (IFG) 
2h plasma 
glucose  ≥200 mg/dl 
140–199 mg/dl 
(IGT) ≥200 mg/dl 140–199 mg/dl (IGT) 
Casual (or 
random) 
plasma 
glucose  ≥200 mg/dl 
 
≥200 mg/dl 
 
Glycated 
hemoglobin ≥6.5% 5.7–6.4% ≥6.5% 
 
 During an OGTT with a loading dose of 75 g 
 In a patient with classic hyperglycemic symptoms 
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2.5. WESTERN BLOT 
 
For immunodetection of MIF and GREM1 in platelet lysates were purified from 
platelets from peripheral blood sample of control subject with normal peripheral 
blood platelets. A standard immunodetection was performed on blotted proteins 
directly after electrotransfer. Protein concentration was determined using Biorad 
Protein Assay with protein standard BSA (Sigma) and measurement of 
absorption at 495 nm. The samples were diluted with Lämmli buffer (5x, +5% 
mercaptoethanol) and heated for 10 min up to 95°C. 30µg of total protein were 
separated on a 15% SDS-polyacrylamide gel electrophoresis (PAGE) 
(Invitrogen). Blotting of the protein onto a polyvinylidenedifluoride membrane 
(PVDF, Immibilon, Millipore) was performed using Semi Dry Transfer Cell 
System (Peqlab). As primary antibody Recombinant Human MIF polyclonal 
antibody from RD Systems was used in 1:7500 dilution in 5% milk/ Phosphate 
buffered saline (PBS) was used for detection of MIF and purified rabbit 
polyclonal GREMLIN (C-Term) antibody from Abgent for detection of 
GREMLIN1. ß-actin antibody (Sigma-Aldrich, Steinheim, Germany) and α-actin 
antibody (polyclonal) (Abcam, Cambridge, UK) were used as internal loading 
control. For detection of antibody binding, corresponding secondary 
fluorescence labeled antibodies and the Odyssey infrared imaging system (LI-
COR, Bad Homburg, Germany) were used. Bands were quantified using 
ImageJ software (National Institutes of Health, USA). 
 
 
2.6. FLUORESCENCE-ACTIVATED CELL SORTING (FACS) 
 
Fluorescence-activated cell sorting was used to quantify the expression of MIF 
and GREM1 from platelets of the subjects. We aimed to quantify the expression 
of the proteins in both stimulated (with 20 µmol/l ADP) and naïve platelets 
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collected from full blood in sodium citrate tubes. 20µL blood were diluted in 980 
µL PBS and 40 µL were aliquoted in every tube.  
 
Activation 
 
The activation of the platelets was performed with 20 µmol/l ADP in a 1:5 ADP: 
blood volume concentration. After pipetting ADP, the dilute was gently swirled to 
mix and was incubated in a dark room at room temperature. After 30 minutes 
2.5 µL 10% paraformaldehyde (PFA) solution was used to fixate the cells.   
 
Multicolour Direct Immunofluorescence Staining 
 
This protocol followed the same steps for unstimulated and activated fixed 
whole blood suspension. After the 2.5 µL 10% PFA solution was added, 5 µL of 
CD42a platelet-specific antibody conjugate were used to threshold data 
acquisition to analyze only platelets.  5µL 1% Triton X-100 (C14H22O (C2H4O)n)  
was used to permeabilize the platelet cell membranes for the tubes, where MIF 
and GREM1 expression was investigated, as preliminary tests had shown better 
results with permeabilized cells in flow cytometry. Another antibody conjugated 
to a different fluorochrome, fluorescein isothiocyanate (FITC), was used to 
simultaneously assess the binding of platelet-associated antibodies. For the 
scope of this study following antibodies were used: 
 
1. Activation-dependent antibodies alpha2b-beta3 (PAC-1) (BD 
Biosciences), P-selectin (CD62P) (R&D Systems) and Stromal Cell-
Derived Factor 1 (SDF-1) (Abcam) 
2. MIF (Abcam) 
3. GREM1 (Abcam) 
 
After an incubation period of 30 minutes in a dark room at room temperature the 
conjugated platelets were fixated with 300 µL PFA 0.5% and the tubes were 
stored at 4° C, protected from light for at least 30 minutes, but not more than 48 
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hours. Right before flow cytometry, samples were vortexed for at least 10 
seconds to gain a proper suspension.  
2.7. IMPEDANCE PLATELET AGGREGOMETRY 
 
The Multiplate® analyzer, a whole blood platelet function assay, was used to 
study the platelet aggregation level. 900µL blood acquired in hirudinized tubes 
(Sarstedt) was needed to perform ADPtest, ASPItest and TRAPtest in each 
patient. The Multiplate® test principle is based on an advancement of Cardinal 
and Flower’s 1979 impedance aggregometry method, the Multiple Electrode 
Aggregometry (MEA)(86). We used the area under the aggregation curve 
(AUC) to express the overall platelet aggregation. U was used as unit for AUC 
(1 Unit * 10 AUC).  Tests were performed at least 30 minutes after blood 
acquisition, but not longer than 3 hours later. 
 
Table 2.3: Reagents used in impedance platelet aggregometry. 
 
Reagent Description 
ADPtest ADP induced platelet activation sensitive to clopidogrel, 
prasugrel and other ADP receptor antagonists 
ASPItest Cyclooxygenase dependent aggregation (using arachidonic 
acid) sensitive to Aspirin®, NSAIDs and other inhibitors of 
platelet cyclooxygenase 
TRAPtest Platelet stimulation via the thrombin receptor (using TRAP-6), 
sensitive to IIb/IIIa receptor antagonists (95) 
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3. RESULTS 
 
3.1. MIF IS EXPRESSED IN HUMAN PLATELETS 
 
3.1.1. DETECTION OF MIF BY WESTERN BLOT 
 
To determine whether MIF is expressed in normal platelets protein was 
harvested from cell lysates and western blot was performed (Fig. 3.1). Blots 
were probed with an anti-MIF rabbit polyclonal antibody and an anti-β actin 
antibody. A specific anti-MIF antibody recognized a single band of 
approximately 12.5 kDa in all specimens tested in resting and activated 
platelets. Peripheral-blood platelets from healthy blood donors were used as 
controls. 
 
Figure 3.1: Qualitative study of MIF expression in platelets 
Western blot analysis of lysates derived from purified platelets from a peripheral 
blood sample from a control subject with normal peripheral blood platelets for 
the expression of MIF. Reducing conditions, 15% SDS-Page, blocking in 5 % 
milk/PBS,(A) 1st Ab Anti-MIF (RD Systems) 1:100 in 5% milk/PBS, (B) 2nd Ab 
1:7500 in 5% milk/PBS. 
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3.1.2. IMMUNOFLUORESCENCE MEASUREMENTS OF MIF BY FACS 
 
Quantitative platelet MIF expression was analyzed by flow cytometry. Flow 
cytometry analysis confirmed the expression of MIF in the three main blood cell 
lineages and a two-color analysis revealed that MIF was highly expressed on 
platelets that were stained with CD42b. CD42b positive cells demonstrated 
prominent surface staining (Figure 3.2.). Before the double staining procedure 
one sample was activated with ADP and one was left in the resting state. The 
total level of fluorescence on a per cell basis was not significantly altered. 
A       
 
B 
 
Figure 3.2: Flow cytometric analysis of the expression of MIF 
Panel A shows flow cytometric plots of whole blood. In the left-hand plot, 
forward and side scatter is demonstrated. The histogram on the right represents 
the expression of CD42b by the three main blood cell lineages.  
Panel B The left-hand plot shows the expression of CD42b on gated MIF cells, 
with two regions showing the CD42+ and CD42b- cell subpopulations. The 
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histogram on the right represents the expression of MIF by the CD42b+ 
subpopulation. 
 
 
3.2. GREM1 IS EXPRESSED IN HUMAN PLATELETS 
 
3.2.1. DETECTION OF GREM1 BY WESTERN BLOT 
 
To determine qualitative expression of GREM1 in platelets, protein was 
harvested from cell lysates and western blot was performed (Fig. 3.3.). Blots 
were probed with an anti-GREM1 rabbit polyclonal antibody and an anti-β actin 
antibody. A specific anti-GREM1 antibody recognized a single band of 
approximately 20.7 kDa followed with a double band of approximately 25 kDa in 
all specimens tested in resting and activated platelets.  
 
Figure 3.3: Qualitative expression of GREM1 in platelets 
Western blot analysis of lysates derived from purified platelets from a peripheral 
blood sample from a control subject showing expression of GREM1 in platelets. 
Reducing conditions, 15% SDS-Page, blocking in 5 % milk/PBS, (A) Ab Anti-
Gremlin (Abgent) 1:100 in 5% milk/PBS, (B) Ab 1:7500 in 5% milk/PBS. 
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3.2.2. IMMUNOFLUORESCENCE MEASUREMENTS OF GREM1 BY FACS 
Platelet GREM1 expression was analyzed by two-colour flow cytometry with 
simultaneous staining with CD42b.  Platelets were studied in both resting and 
activated state without an alteration of total level fluorescence on a per cell 
basis. 
A 
 
B 
 
Figure 3.4: Flow cytometric Analysis of the Expression of GREM1 
Panel A shows flow cytometric plots of whole blood. In the left-hand plot, 
forward and side scatter of blood is demonstrated. The histogram on the right 
represents the expression of CD42b by all cell subpopulations.  
Panel B The left-hand plot shows the expression of CD42b on gated GREM1 
cells, with two regions showing the CD42+ and CD42b- cell subpopulations. 
The histogram on the right represents the expression of GREM1 by the CD42b+ 
subpopulation.  
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3.3. STUDY SUBJECTS’ CHARACTERISTICS 
 
The study included 300 CAD patients. Mean study participant age was 67.7 
years and more than fifty per cent were of age older than 70 years. More than 
three quarters were men, with women on average being older than men with a 
mean age of 71.8 (± 10.4) years versus 66.4 (± 11.6) years. Mean body-mass 
index was 29.2 (± 18.9). One quarter of the subjects were active smokers when 
enrolled in the study, while 54.3% of them had never been smokers. Diabetes 
mellitus was common between subjects, with 31.7% having some form of 
insulin resistance. Amongst the diabetics those under therapy with oral anti-
diabetic agents had the poorest control of blood glucose levels and those under 
insulin the best one (HbA1c: 8.63 (± (2.3) g/dL versus 8.09 (± 0.96) g/dL).  From 
the 95 diabetics 51 (54%) had a HbA1c over 7 g/dL. The mean total cholesterol 
levels were 176.4 (± 41.8) mmol/L with LDL 129.5 (± 39.2) mmol/L. Fifty five 
subjects suffered from chronic kidney disease with a mean serum creatinine 
value of 1.54 (± 1.5) mg/dL and mean serum Urea value of 55.69 (± 25.4) 
mg/dL. Patients without known chronic kidney disease had a mean serum 
creatinine value of 0.93 (± 0.2) mg/dL. More than 25% of the subjects had some 
family history of coronary artery disease and 78.7% had hypertension requiring 
medication. Table 3.1. shows the patients’ characteristics. 
 
 
 
Table 3.1. Baseline characteristics of the patient cohort 
Characteristic Total (300) 
Age 
 
30–59 years 72 
60–69 years 71 
≥70 years 155 
 38 
Mean age — yr. 67.7 (±11.6) 
Sex 
 
Male sex — no. (%) 228 (76) 
Female sex — no. (%) 72 (24) 
BMI † — mean kg/m² 29.2 (±18.9) 
Smoking status 
 
Current smoker — no. (%) 75 (25) 
Former smoker — no. (%) 62 (20.7) 
Never smoker — no. (%) 163 (54.3) 
History of diabetes — no. (%)  
 
No known diabetes — no. (%)  205 (68.3) 
Type 1 diabetes — no. (%)  0 
Type 2 diabetes — no. (%)  95 (31.7) 
Low glycemic index diet — no. (%)  20 (6.7) 
Oral anti-diabetic medication — no. (%)  38 (12.7) 
Insulin — no. (%)  37 (12.3) 
HbA1c (g/dL), median (IQR‡) 7.2 (±4.2) 
HbA1c > 7 g/dL 51 
Total cholesterol — mg/dL 176.4 (±41.8) 
LDL cholesterol  129.5 (±39.2) 
Chronic kidney disease — no. (%) 55 (18.3) 
Serum creatinine value (mg/dL), median (IQR‡) 1.05 (±0.7) 
Family history of coronary artery disease — no. (%) 79 (26.3) 
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Hypertension requiring medication — no. (%) 236 (78.7) 
Clinical presentation 
 
Stable angina pectoris — no. (%) 131 (43.6) 
Unstable angina pectoris — no. (%) 67 (22.3) 
NSTEMI — no. (%) 69 (23) 
STEMI — no. (%) 33 (11) 
History of known coronary artery disease — no. (%) 248 (82.7) 
NYHA I 140 (46.7) 
NYHA II 101 (33.7) 
NYHA III 41 (13.7) 
NYHA IV 18 (6) 
Ejection fraction 47.14 (±10.6) 
Atrial fibrillation 58 (19.3) 
Loge CRPŦ — mg/liter  
CRP Day 0 (mg/dl), median (IQR‡) 1.62 (±3.9) 
Biomarkers of cardiac injury 
 
Troponin Imax (µg/dL) 5 (±28.4) 
Creatinine kinase (mg/dL) 276.9 (±668.2) 
Medication on presentation 
 
Aspirin 179 (59.7) 
Anticoagulants 27 (9) 
Clopidogrel 37 (12.3) 
Prasugrel 7 (2.3) 
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Ticagrelor 12 (4) 
  
* Values represent means ±SD.  
 
† BMI=body-mass index 
 
‡IQR, Interquartile range 
 
ŦCRP, C-reactive protein 
 
 
 
 
131 elective patients with stable CAD were included in this cohort. 40 of them 
had a myocardial infarction in their medical history at a mean of 5.5 years 
before their current presentation. The mean left ventricular ejection fraction in 
this group was 45.9 (± 10.6) % and the mean age was 68.23 (± 10.6) years. 
The distribution of weight was normal with a mean weight of 83.3 kg and 
standard deviation of 13.6 kg. Their mean BMI was 28.7 (± 4.37) kg/m2, their 
mean LDL 127.56 (± 44.7) mmol/L, their Creatinine 0.97 (± 0.26) mg/dL and 43 
of them were diabetics. Furthermore they had a Creatinine kinase within the 
normal with 107.23 (± 62.7) U/L and a CRP of 0.6 (± 0.88) mg/dL. 
 
The remaining 169 patients presented with an acute coronary syndrome. 67 
patients or 22.3% were diagnosed with an unstable angina pectoris, 69 or 23% 
with a non ST-Segment Elevation Acute Coronary Syndrome and 33 patients or 
11% presented with ST-segment elevation acute myocardial infarction. Patients 
with unstable angina pectoris were the oldest group with a mean age of 70.78 
(± 10.49) years and patients with STEMI were the youngest group with a mean 
age of 61.29 (± 12.27) years. Furthermore, left ventricular ejection fraction was 
most impaired in the STEMI group with a mean EF of 47.85 (± 6.53) % and less 
impaired in the unstable angina group, where the patients had a mean EF of 
49.48 (± 11.33) %. Overall the STEMI group included the least multimorbid 
patients in the ACS-group, including better renal function (mean Creatinine of 1 
(± 0.64) mg/dL versus 1.2 (± 1.3) mg/dL in the unstable angina pectoris group 
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and 1.04 (± 0.35) mg/dL in the NSTEMI-group), better glucose control (with 
mean glycated hemoglobin of 5.19 (± 1.6) % versus 6.46 (± 1.01)% in the 
unstable angina group and 7.44 (± 1.74)% in the NSTEMI group) and less 
obese patients (with mean BMI of 25.55 (± 1.84) kg/m2 versus 27.18 (± 3.64) 
kg/m2 in the unstable angina group and 28.06 (± 5.28) kg/m2). 
 
Depending on their diabetes status patients were classified in non-diabetics, 
patients with diabetes that requires lifestyle changes to control, diabetics who 
need oral agents to control their glucose levels and patients who require 
treatment with insulin. There were 95 diabetics included in this study. Diabetics 
were in general older with a mean age of 70.8  (± 10.2) years versus 66.3 (± 
11.9) years for the non-diabetics, without any statistical significance (p= 0.54). 
They had a slightly worse ejection fraction with 49.25 (± 11.2)% versus 51.25 (± 
11.5)%, also with no statistical significance (p= 0.585). Furthermore diabetics 
had a slightly higher BMI with a mean of 28.95 (± 5.26) kg/m2 versus 27.57 (± 
3.8) kg/m2 (p= 0.009). Their LDL-Cholesterol levels were better controlled, since 
more of them were under therapy with statins (124.34 (± 32.4) mg/dL in 
diabetics versus 131.99 (± 42.1) mg/dL in non-diabetics, p= 0.143). The levels 
of C-reactive protein in diabetics were slightly higher in comparison with non-
diabetics (2.04 (± 4.7) mg/dL in diabetics versus 1.42 (± 3.4) mg/dL in non-
diabetics, p= 0.44). Mean serum creatinine levels did not differ significantly with 
diabetics having a mean creatinine of 1.09 (± 0.42) mg/dL and non-diabetics 
1.03 (± 0.8) mg/dL (p= 0.381).  The following table sums up the characteristics 
of the cohort according to their diabetes status. 
 
Table 3.2. Baseline Characteristics according to diabetes status 
Characteristic 
Diabetics 
(95) 
Nondiabetics 
(205) 
Mean age — yr. 70.82 (± 10.2) 66.3 (± 11.9) 
Male sex — no. (%) 66 (69.5) 162 (79) 
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BMI † — mean kg/m² 28.9 (± 5.3) 27.6 (± 3.8) 
Smoking status 
  
Current smoker — no. (%) 14 (14.7) 61 (29.8) 
Former smoker — no. (%) 21 (22.1) 41 (20) 
Never smoker — no. (%) 60 (63.2) 103 (50.2) 
HbA1c (g/dL), median (IQR‡) 8.3 (± 5.4) 5.8 (± 0.5) 
Total cholesterol — mg/dL  169 (±34) 179.9 (44.7) 
LDL cholesterol — mg/dL 124.34 (±32.4) 132 (±42.1) 
Chronic kidney disease — no. (%) 30 (31.6) 25 (12.2) 
Serum creatinine value (mg/dL),  
median (IQR‡) 1.09 (±0.4) 1.03 (± 0.8) 
Family history of coronary artery  
disease — no. (%) 20 (21.1) 59 (28.8) 
Hypertension requiring medication 
 — no. (%) 82 (86.3) 154 (75.1) 
Clinical presentation 
  
Stable angina pectoris — no. (%) 13 (45.3) 88 (42.9) 
Unstable angina pectoris — no. (%) 20 (21.1) 47 (22.9) 
NSTEMI — no. (%) 25 (26.3) 44 (21.5) 
STEMI — no. (%) 7 (7.4) 26 (12.7) 
History of known coronary artery  
disease — no. (%) 86 (90.5) 162 (79) 
NYHA I 40 (42.1) 100 (48.8) 
NYHA II 34 (35.8) 67 (32.7) 
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NYHA III 12 (12.6) 29 (14.1) 
NYHA IV 9 (9.5) 9 (4.4) 
Ejection fraction 49.25 (± 11.2) 51.21(± 11.5) 
Atrial fibrillation 32 (33.7) 26 (12.7) 
Baseline CRP (mg/dl), median (IQR‡) 2.04 (±4.7) 1.42 (± 3.36) 
Biomarkers of cardiac injury 
 
Troponin Imax (µg/dL) 11.26 (± 21.73) 24.49 (± 51.05) 
Creatinine kinasemax (mg/dL) 526.8 (± 1177) 712.6(± 1009) 
Medication on presentation 
 
Aspirin 68 (71.6) 111 (54.1) 
Anticoagulants 13 (13.7) 14 (6.8) 
Clopidogrel 12 (12.6) 4 (2) 
Prasugrel 3 (3.2) 4 (2) 
Ticagrelor 7 (7.4) 5 (2.4) 
   
 
* Plus–minus values are means ±SD.  
 
† BMI=body-mass index 
  
‡ IQR, Interquartile range 
  
ŦCRP, C-reactive protein 
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3.4. PLATELET MIF AND GREM1 EXPRESSION ARE INDEPENDENT OF 
PLATELET COUNT 
 
In our cohort the mean platelet count was 250 (± 74) thousands/µL. We found 
that expression of MIF in platelets was independent from platelet count with a 
mean MFI value of 17.76 (± 9.7) and a p value of 0.222. In activated state the 
mean MFI value for the expression of MIF was 16.63 (± 11.38) (p= 0.419). For 
GREM1 from resting platelets a mean MFI of 15.38 (± 7.49) was found (p= 
0.530), whereas for GREM1 from platelets activated with ADP the mean MFI 
value was 16.14 (± 9.48) (p= 0.338). 
 
 
 
 
Figure 3.5: Scatterplot presenting the correlation of the mean values of MFI of 
MIF (above) and GREM1 (below) with the platelet count in our cohort.  
 
 
3.5. PLATELETS STIMULATED WITH ADP PRODUCE DIFFERENT 
AMOUNTS OF MIF AND GREM1 
 
We compared the expression of MIF and GREM1 in resting and activated 
platelets. The platelets were activated with ADP before staining as described 
above. MIF levels in resting platelets were 17.98 (± 9.8), while in activated ones 
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16.9 (± 11.7). GREM1 levels in resting platelets were at mean 15.58 (± 7.7) and 
in activated ones 16.53 (± 10.6) MFI. The levels of MIF and MIF + ADP 
correlated significantly with a p value of 0.006 and a correlation coefficient of 
0.706. The levels of GREM1 and GREM1 + ADP also correlated significantly 
with a p value of 0.004 and a correlation coefficient of 0.743. 
 
Figure 3.6: Scatterplots presenting the correlation of the mean values of MFI of 
MIF with MIF in platelets stimulated with ADP (above) and GREM1 in resting 
platelets and GREM1 in platelets stimulated with ADP (below) in our cohort. R2 
coefficient of determination was 0.706 for MIF and 0.743 for GREM1. 
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3.6. THE LEVELS OF MIF EXPRESSED BY PLATELETS CORRELATES 
WITH THE EXPRESSION OF GREM1 IN THE SAME PATIENT 
 
Our cohort expressed MIF from platelets with a mean MFI value of 17.98 (± 
9.77) and GREM1 with a mean MFI value of 15.65 (± 8.08). These mean values 
correlated significantly in our patients with a p value <0.001. 
 
 
Figure 3.7: Scatterplot presenting the correlation of the mean values of MFI of 
MIF and GREM1 in our cohort. R2 coefficient of determination was 0.48.  
 
 
3.7. P-SELECTIN PLATELET EXPRESSION CORRELATES WITH MIF AND 
GREM1 EXPRESSION 
 
We compared the expression of P-selectin with the expression of MIF. MIF 
levels were found higher in patients with high CD62P-expression (18.55 ± 9.9 
versus 13.28 ± 6.42, p= 0.044). Platelets that showed a high expression of P-
selectin appeared to also express higher amounts of Gremlin-1 (14.9 ± 6.2 
versus. 10.4 ± 2.6, p=0.03). 
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Figure 3.8: Scatterplots presenting the correlation of the mean fluorescence 
intensity of MIF (left) and GREM1 (84) with values for P-selectin in our cohort. 
R2 coefficient of determination was 0.223 for MIF (p=0.044) and 0.264 for 
GREM1 (p=0.03). 
 
 
3.8. PLATELET REACTIVITY AS MEASURED WITH MULTIPLATE® 
ANALYSER WAS INDEPENDENT FROM MIF AND GREM1 EXPRESSION 
 
MIF and GREM1 expression in resting and activated platelets did not correlate 
with platelet aggregation induced with ADP, ASPI or TRAP-6 as measured with 
the Multiplate® analyzer. For MIF and ADP-test the Pearson correlation was   
0.021 (p= 0.747) for resting and 0.049 (p= 0.447) for stimulated platelets. For 
GREM1 and ADP-test the Pearson correlation coefficient was 0.051 (p= 0.383) 
for resting and 0.067 (p= 0.256) for stimulated platelets. The ASPI and TRAP-6 
tests yielded comparable results with ASPI-test units showing no correlation 
neither with MIF or GREM1 levels (p= 0.933 and 0.675 in resting platelets and 
p= 0.606 and 0.870 in stimulated platelets, respectively). P values for 
correlation with TRAP-induced aggregation were 0.89 for MIF in resting 
platelets and 0.931 in stimulated ones and for GREM1 0.491 and 0.672, 
respectively. 
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When 40 AUC (Area Under the Curve) was used as cut-off value for high 
platelet reactivity (HPR) in patients on both aspirin and an ADP-receptor 
inhibitor, no correlation of HPR with GREM1 and MIF levels was found. This 
cut-off value was selected according to the consensus and update on the 
definition of on-treatment platelet reactivity to adenosine diphosphate state of 
art paper and the experience of our institution (86, 137, 138, 141) 
 
Patients with HPR had a mean MIF value of 16.66 (± 10.6) versus 16.59 (± 
6.98), p= 0.038. GREM1 levels were found with a mean value of 17.91 (± 9.67) 
in patients with HPR and 14.58 (±7.19) in patients with and less than 40 AUC at 
ADP-test (p= 0.077). 
 
 
 
Figure 3.9: Scatterplots presenting the correlation of the mean fluorescence 
intensity of MIF and GREM1 with values of platelet aggregation as measured 
after stimulation with ADP (AUC) in our cohort.  
 
 
3.9. LEVELS OF MIF AND GREM1 EXPRESSION FROM PLATELETS 
CORRELATE WITH THE LEVELS OF GLYCOPROTEIN VI EXPRESSION 
FROM PLATELETS 
 
There was a weak correlation between platelet MIF and Glycoprotein VI 
expression as shown with a Pearson-test value of 0.249 or p<0.001 in resting 
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platelets and 0.148 or p= 0.023 in stimulated platelets. Correlation between 
GREM1 and Glycoprotein VI was also found to be statistically significant with p 
values of <0.001 for resting and 0.003 for activated platelets. 
 
 
Figure 3.10: Scatterplots presenting the correlation of the mean values of MFI of 
MIF (above) and GREM1 (below) with a mean fluorescence intensity of SDF-1 
in our cohort.  
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3.10. LEVELS OF MIF AND GREM1 EXPRESSION FROM PLATELETS 
CORRELATE WITH THE LEVELS OF PAC-1 EXPRESSION FROM 
PLATELETS 
 
There was a correlation between platelet MIF and PAC-1 expression as shown 
with a Pearson-test value of 0.498 or p<0.001 in resting platelets and 0.517 or 
p<0.001 in stimulated platelets. Correlation between GREM1 and PAC-1 was 
also found to be statistically significant with p values of <0.001 for resting 
(rs=0.364) and activated (rs=0.417) platelets. Platelets with high amount of PAC-
1 had a high amount of MIF and GREM1 (MIF: 24.6 (± 11.4) MFI versus 15.8 (± 
8) MFI, GREM1: 19.7 (± 11.4) MFI versus 14.1 (± 5.4) MFI). 
 
 
3.11. LEVELS OF GREM1 EXPRESSION FROM PLATELETS AND PLASMA 
LEVELS CORRELATE WITH CARDIAC NECROSIS MARKER CREATININE 
KINASE 
 
Levels of platelet bound GREM1 showed a weak correlation with the maximum 
creatinine kinase values with a correlation coefficient of 0.174 and a p value of 
0.047. Levels of plasma GREM1 showed a correlation with the creatinine kinase 
levels with a correlation coefficient of 0.158 and a p value of 0.038. 
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A 
 
 
 
 
B 
 
Figure 3.11: Scatterplot presenting the correlation of the values of plasma levels 
of GREM1 (A) and mean MFI values of platelet GREM1 (B) with creatinine 
kinase in our cohort.  
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3.12. LEVELS OF GREM1 AND MIF EXPRESSION FROM PLATELETS 
CORRELATE WITH TROPONIN I 
 
Levels of GREM1 showed a statistical correlation with the maximum values of 
Troponin I with a correlation coefficient of 0.243 (p= 0.006), while MIF and 
Troponin levels had a correlation coefficient of 0.233 (p= 0.014). Patients with 
positive troponin tests (cut-off 0.004 µg/dL) showed lower expression of MIF 
and GREM1 in their platelets with mean MFI values of 16.59 (± 9.8) versus 
18.96 (± 9.8) for MIF and 14.42(± 7) versus 16.21 (± 7.9) for GREM1. 
 
 
 
Figure 3.12: Scatterplots presenting the correlation of the mean MFI values of 
MIF (left) and GREM1 (84) to Troponin values in patients with positive 
Troponin-test in our cohort. 
 
 
3.13. LEVELS OF SERUM CRP, MIF AND GREM1 EXPRESSION FROM 
PLATELETS ARE INCREASED IN DIABETICS 
 
We observed that C-reactive protein levels are increased in diabetics in 
comparison to non-diabetics. Diabetics had a mean CRP in serum of 2.04 (± 
4.715) mg/dL in comparison to non-diabetics that had a mean serum CRP of 
1.42 (± 3.356) mg/dL. This difference was found statistically significant with a p 
value of 0.044. Platelets of diabetics expressed MIF significantly more with a 
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mean MFI value of 18.67 (± 11.257) in comparison to non-diabetics, whose 
platelets expressed MIF with a mean MFI value of 17.66 (± 9.03) (p= 0.004). 
GREM1 was also expressed stronger in platelets of diabetics with a mean MFI 
value of 15.78 (± 8.399) versus 15.49 (± 7.428) in those of non-diabetic 
patients. (p=0.022).  
 
 
 
 
Figure 3.13: Clustered bar presenting the mean values of CRP, MIF and 
GREM1 and the standard error of the mean in correlation with diabetic status of 
the subjects.  
 
 
3.14. ONGOING THERAPY REGIMENT FOR DIABETES DID NOT 
CORRELATE WITH THE EXPRESSION OF MIF FROM PLATELETS 
 
 54 
The expression of MIF showed no significant intergroup differences in platelets 
of diabetics undergoing lifestyle changes to control their glucose levels and 
platelets of diabetics requiring oral antidiabetic drugs (mean MFI 16,65 (± 11,2) 
versus 18.6 (± 9.7), p= 0.366). MIF expression levels of diabetics requiring 
therapy with insulin were as high as 19.8 (± 12.7), but the difference showed no 
statistical significance with a p value of 0.201 when compared to diabetics using 
oral antidiabetic drugs and a p value of 0.773 when compared with those 
undergoing lifestyle changes. A trend of increased MIF expression from 
platelets depending to the therapeutic regiment required was just arithmetically 
apparent. 
 
 
3.15. MIF EXPRESSION FROM PLATELETS CORRELATES WITH THE 
SUCCESS IN CONTROLLING GLUCOSE LEVELS IN CAD PATIENTS 
 
A comparison of MIF levels with the quality of glucose level controls, using 
HbA1c, showed a statistical correlation. MIF was expressed stronger in platelets 
of patients with a poor control of their diabetes with a mean MFI value of 20.94 
(± 12.32) versus 13.65 (± 4.1) in those with an HbA1c lower than 7% (p= 
0.003).  
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Figure 3.14: Bar chart representing MFI of MIF from resting and MIF from 
activated platelets with HbA1c as the discrete data set, stratifying patients to 
those with well controlled diabetes (HbA1c <7%) and those with poor control 
over their average plasma glucose concentration (HbA1c ≥7%). 
 
 
3.16. GREM1 EXPRESSION IN PLATELETS CORRELATES WITH THE 
SUCCESS IN CONTROLLING GLUCOSE LEVELS IN CAD PATIENTS 
 
The expression of GREM1 in platelets showed a statistical increase in patients 
with poorly controlled diabetes mellitus independent of the therapy. This 
increase was present in both resting and activated platelets. For patients with 
an HbA1c ≥7% GREM1 expression in resting platelets had a mean MFI value of 
17.98 (± 10.82) versus 13.65 (±4.1) in those with control over their average 
plasma glucose concentration (p= 0.005). In activated platelets of patients with 
poorly controlled diabetes GREM1 was expressed with a mean MFI value of 
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19.82 (± 13.56) versus 13.23 (± 5.4) in those with an HbA1c under 7% (p= 
0.001).  
 
 
 
Figure 3.15: Bar chart representing MFI of GREM1 from resting and GREM1 
from activated platelets with HbA1c as the discrete data set, stratifying patients 
to those with well controlled diabetes (HbA1c <7%) and those with poor control 
over their average plasma glucose concentration (HbA1c ≥7%). 
 
 
3.17. MIF AND GREM1 PLATELET LEVELS ARE LOWER IN PATIENTS WITH 
IMPAIRED EJECTION FRACTION 
 
The ejection fraction as assessed by contrast ventriculography correlated with 
the mean MIF levels in resting platelets and activated ones. Quiescent platelet 
from patients with left ventricular dysfunction (ejection fraction (<45%) express 
less MIF with a mean MFI of 3.4 (± 0.7) versus 4.1 (± 1) MFI in those without a 
relevant impairment (p< 0.001). Activated platelets also expressed less MIF in 
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patients with left ventricular dysfunction with a mean MFI of 3.2 (± 0.8) versus 
3.9 (± 1) mean MFI in those without a relevant impairment (p<0.001). 
 
GREM1 expression in platelets of patients with left ventricular dysfunction was 
decreased in comparison with patients with no relevant left heart failure, with 
mean MFI 3.5 (± 0.4) versus 3.9 (± 0.8) (p=0.005) for resting platelets and 
mean MFI 3.6 (± 0.6) versus 3.9 (± 1) for activated platelets (p=0.046). 
 
 
3.18. MIF AND GREM1 PLATELET LEVELS ARE SIGNIFICANTLY LOWER IN 
ACS PATIENTS WITH IMPAIRED EJECTION FRACTION 
 
Patients suffering from systolic heart failure during an ACS have significantly 
lower levels of platelet MIF and GREM1. Patients in heart failure were 
considered patients with an ejection fraction under 45% as assessed by cardiac 
ventriculography.  
 
Platelet MIF expression in patients with left ventricular dysfunction during an 
ACS was decreased in comparison with patients with no relevant left heart 
failure, with a mean MFI 3.35 (± 0.8) versus 4 (± 1) (p=0.004) for resting 
platelets and mean MFI 3.1 (± 0.8) versus 3.9 (± 1) for activated platelets 
respectively (p=0.001). Platelet GREM1 expression in patients with left 
ventricular dysfunction during an ACS was decreased in comparison with 
patients with no relevant left heart failure, with a mean MFI 3.4 (± 0.4) versus 
3.9 (± 0.9) respectively (p=0.008). 
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Figure 3.16: Bar chart presenting the correlation of MIF and GREM1 in platelets 
with the ejection fraction assessed by ventriculography. We classified impaired 
left ventricular function as left ventricular ejection fraction <45 percent and as 
non-impaired EF ≥45%. 
 
 
3.19. THE CLINICAL PRESENTATION OF IHD CORRELATES WITH THE 
LEVELS OF MIF AND GREM1 EXPRESSED BY PLATELETS 
 
The different clinical presentations of ischemic heart disease were found to 
correlate highly with MIF and GREM1 levels in resting and activated platelets. 
Platelet levels of MIF decrease as the acuteness of the ischemic disease 
increases. Mean MFI value of MIF in patients with stable angina was 4.3 (± 1), 
in patients with unstable angina 4.1 (± 1.2), in patients with non-STEMI 
infarction was 3.8 (± 1.1) and in patients presenting with an ST-elevation ACS 
was found the lowest with a mean value of 3.8 (± 0.9). The difference between 
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expression of MIF in stable CAD and heart attacks was statistically significant 
with a p value of 0.006 for stable CAD and NSTEMI and 0.034 for stable CAD 
and STEMI. 
 
GREM1 levels in stable ischemic heart disease were found at a mean value of 
3.9 (± 0.8) MFI when in STEMI patients 3.6 (± 0.7) MFI (p=0.028). 
 
MIF levels in platelets of patients with ACS were 3.9 (± 1.1) MFI versus 4.3 (± 1) 
MFI in patients with a stable angina  (p= 0.008). GREM1 platelet expression in 
patients with ACS was found lower with a mean MFI of 15.3 (± 8.4) versus 16 (± 
6.8) in patients with a stable CAD (p=0.029). 
 
 
 
Figure 3.17: Bar chart representing the mean MFI for MIF (white) and GREM1 
(black) depending on the presence of ACS. 
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3.20. PLASMA LEVELS OF GREM1 CORRELATE WITH PLASMA CRP 
LEVELS 
 
GREM1 levels in serum as evaluated with ELISA showed a correlation with C-
reactive protein levels with a Spearman’s rho of 0.179 and a p value of 0.014. A 
non-parametric test was used because CRP values had a skewed distribution 
and also allows for inclusion of outliers. The cut-off value used for CRP was 0.5 
mg/dL. Patients with positive CRP had a mean GREM1 of 288 (± 137) pg/mL 
and patients with CRP values under 0.5 mg/dL had a mean GREM1 value of 
249 (± 132) pg/mL. 
 
 
3.21. PLASMA LEVELS OF GREM1 AND MIF WERE INDEPENDENT OF 
WHITE BLOOD CELL COUNT  
 
Total white blood cell count did not affect plasma levels of both GREM1 and 
MIF with a correlation coefficient for MIF of 0.47 (p= 0.532) and for GREM1 of 
0.85 (p= 0.250). 
 
 
3.22. PLASMA LEVELS OF GREM1 CORRELATED WITH RENAL FUNCTION 
MARKER  
 
Plasma levels of GREM1 showed a weak correlation with the values for serum 
creatinine with a correlation coefficient of 0.178 and p-value of 0.015 and with 
the serum urea levels with a correlation coefficient of 0.216 with a p-value of 
0.006. 
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3.23. PLATELET BOUND GREM1 AND MIF EXPRESSION IS INDEPENDENT 
OF CONCOMITANT MEDICATION  
 
The platelet expression of MIF in patients under aspirin-therapy was compared 
to the MIF expression of aspirin-naïve patients and no significant difference was 
found (p= 0.105). The platelet expression of MIF in patients under dual 
antiplatelet regiment with aspirin and a P2Y12-inhibitor was compared to 
patients’ naïve to both medications and no significant difference was found (p= 
0.154 for clopidogrel, p= 0.790 for prasugrel and p= 0.618 for ticagrelor). 
The platelet expression of GREM1 in patients under aspirin-therapy was 
compared to the GREM1 expression of aspirin-naïve patients and no significant 
difference was found (p= 0.203). The platelet expression of GREM1 in patients 
under dual antiplatelet regiment with aspirin and a P2Y12-inhibitor was 
compared to patients’ naïve to both medications and no significant difference 
was found (p= 0.998 for clopidogrel, p= 0.859 for prasugrel and p= 0.405 for 
ticagrelor). 
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4. DISCUSSION 
 
4.1. MIF IN CORONARY ARTERY DISEASE AND TYPE 2 DIABETES 
MELLITUS 
 
In this study we concentrated on the atherogenic function of MIF.  The role of 
monocytes, T-cells and activated endothelium in the circle of MIF-expression 
has already been broadly implicated in atherosclerosis. Our group has 
managed to show that plasma MIF expression is enhanced in ACS, is 
associated with various markers of inflammation and that it correlated with 
cardiac necrosis markers after PCI (110). In other studies it has been shown 
that genetic manipulation and deletion of MIF in atherosclerosis susceptible 
mice protected the heart from severe ischemia-reperfusion injury through 
suppression of inflammatory responses (63). 
 
This study provides new knowledge concerning the clinical role of platelet 
bound MIF in cardiovascular disease. Many mechanisms of MIF in 
atherosclerosis have been proposed; promotion of atherogenic leukocyte 
recruitment processes has been recognized as a major underlying mechanism 
of the role of MIF in plaque instability (23, 136). 
 
Vascular injury might precede atherothrombosis and MIF has been proved to 
regulate the biological response to injured tissue. In a study model of carotid 
artery injury in atherosclerosis-susceptible mice MIF was shown to promote 
thickening of the neointima through accumulation of inflammatory cells and 
proliferation of the media and intima layer (34). A study about the interaction of 
MIF with AMP-activated protein kinase (AMPK) suggested a critical role for MIF 
in the cardiomyocyte response to ischemia, implicating MIF-release genes in 
ATP-regulation in cardiomyocytes and suggesting MIF genes as a diagnostic 
target in risk stratification for CAD (105). 
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Platelets are recruited to the site of vascular injury to fulfill their hemostatic role, 
but also at sites of activated, inflamed but still intact endothelium and promote 
atherosclerosis (21). Platelets are a major part of thrombi in acute myocardial 
infarctions and their proinflammatory mediators might contribute to fibrosis and 
systolic dysfunction following myocardial infarctions (101). Thus, the expression 
and regulation of the expression of MIF from platelets poses an interesting 
investigational target. 
 
In several clinical studies serum MIF levels correlated with insulin resistance 
and metabolic syndrome, providing support for a role of MIF in the development 
of insulin resistance and T2DM (76, 158). However, in the large Finnish 
Diabetes Prevention Study which tested lifestyle intervention in patients with 
BMI> 25 kg/m2 with impaired glucose tolerance, MIF was not associated with 
the risk of T2DM in the control group and subjects with high MIF had lower risk 
for T2DM (77). Clinical studies so far have suggested an important link between 
MIF, obesity, insulin resistance and T2DM, but it is not clear if the MIF 
expression irregularities are epiphenomena or casual factors. Animal studies 
showed that MIF-Knockout mice had increased glucose uptake into white 
adipose tissue, with MIF inhibiting insulin signal transduction, overall suggesting 
an important role for MIF in the regulation of systemic glucose metabolism 
during infection and tissue invasion (10). 
 
There is a growing body of evidence on platelets and their role in the 
progression of the atherosclerotic procedure through modulation of immune 
responses. Many pathways for that interaction have been suggested such as 
the OxLDL-mediated platelet-monocyte aggregate formation theory highlighting 
the role of platelets in atherosclerotic plaque development and plaque 
destabilization (11, 14). This project is based on an observation that platelets 
contain significant amounts of MIF and GREM1.  
 
Chronic low-grade inflammation is a hallmark of T2DM, a process guided from 
cytokines, including the macrophage migration inhibitory factor. The role of MIF 
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in T2DM has been extensively studied. Several clinical studies have found 
slightly elevated serum MIF levels in patients with T2DM (150). Higher MIF 
levels were found in patients in pro-diabetic states spawning the theory of MIF 
level elevation preceding the onset of T2DM (58, 76, 88). These higher levels of 
MIF were shown to be a risk factor for coronary events in diabetics and 
especially to mediate myocardial damage (97). 
 
Hence, MIF is one of the chemokines that directly relate to T2DM and risk for 
coronary disease. It has been suggested that it contributes to coronary disease 
development in diabetics indirectly through stimulation of the production of other 
cytokines. It also stimulates certain inflammatory adipocytokines promoting 
insulin resistance and creating a vicious circle (130). 
 
4.2. GREMLIN-1 AS AN ENDOGENOUS ANTAGONIST OF MIF AND ITS 
ROLE IN ATHEROSCLEROSIS 
 
Gremlin is a highly conserved 184 amino acid protein (20.7 kDa), which 
contains a cysteine-rich region and a cysteine knot motif, a structure shared by 
members of the TGF-β superfamily. Gremlin exists in both secreted and cell 
associated forms.  This pattern of expression permits its binding to extracellular 
BMP-2, BMP-4 and BMP-7 and inhibition of smad-1, smad-5 and smad-8 
signaling, when expressed on membranes of renal cells (165) or alternatively 
binding to the slit1 and slit2 receptor when expressed on monocyte membranes 
to act as negative modulator of monocyte chemotaxis (79). These are some of 
many possibly existing mechanisms of gremlin regulation of cellular behavior. 
High glucose levels have been showed to increase gremlin mRNA in pericytes 
and mesangial cells, implicating GREM1 in the pathogenesis of diabetic 
nephropathy and retinopathy (85, 100, 153). 
 
The role of GREM1 in diabetes and coronary heart disease has not been 
adequately investigated. However, since it has been shown that it acts as an 
antagonist of MIF (109) it was interesting to investigate the correlation of 
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GREM1 and MIF levels in patients with IHD and diabetes. Regarding the role of 
GREM1 in atherosclerosis, gremlin-1 expression has been identified in humans 
at sites of arterial injury and has been shown that GREM1 inhibits MIF-induced 
foam cell formation and monocyte and macrophage adhesion on the 
atherosclerotic vessel wall, and reduces substantially plaque size and plaque 
foam cell content in ApoE-/- mice in vivo (109). 
 
It has also been shown that Gremlin1 induces a proinflammatory response in 
endothelial cells causing reactive oxygen species and cyclic adenosine 
monophosphate production and the upregulation of proinflammatory molecules 
involved in leukocyte extravasation like vascular cell adhesion molecule-1 
(VCAM-1), results that suggest a cross-talk between angiogenesis and 
inflammation and demonstrate a role of gremlin in the proinflammatory/ 
proangiogenic response (35). 
 
4.3. EXPRESSION OF GREM1 AND MIF IN OUR GROUP OF PATIENTS 
WITH IHD 
 
We managed to detect substantial levels of GREM1 and MIF proteins in lysates 
of platelet populations of healthy individuals, recognizing human platelet MIF as 
a 12.5 kDa protein and GREM1 as a band of approximately 20.7 kDa followed 
by a double band of approximately 25 kDa. Substantial levels of MIF and 
GREM1 were found through flow cytometry in platelet populations of patients 
with CAD.  
 
Platelet bound MIF and MIF plasma levels correlated significantly in our study 
suggesting that platelets are probably a relevant source of plasmatic MIF and 
suggesting a cross talk between cells producing MIF and a complex regulation 
of its expression. The plasma levels of MIF were found to be independent of the 
white blood cell count; the same applied for GREM1 plasma levels. Furthermore 
GREM1 and MIF platelet bound levels were also independent from platelet 
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count in peripheral blood. Of note was that plasma levels of GREM1 correlated 
significantly with plasma levels of CRP.  
 
We also managed to show that the levels of the two investigated proteins in 
human platelets correlate to each other statistically significantly with a p value of 
0.0001. These findings are in accordance with a theory of variability of 
expression of these proteins depending on the inflammation status of the 
human organism and not the cell count itself. However, such findings suggest 
that platelets are an important vehicle for MIF and GREM1 through the 
cardiovascular system and that GREM1 and MIF production are regulated 
through the interaction of the two proteins.  
 
Platelet-bound expression of MIF and GREM1 were found independent of 
platelet count and platelet reactivity status. High platelet reactivity can be 
considered a risk factor for post-PCI stent thrombosis and myocardial infarction, 
while patients with T2DM consist a high-risk group as they exhibit increased 
platelet reactivity (98, 133), but the clinical usefulness of platelet function testing 
and its role as an independent risk factor is still under question (48, 65, 86). 
 
The expression and induction of CD62p indicating release reaction of α-
granules and PAC-1 directed against activation-dependent epitopes on 
GPIIb/IIIa and GPVI expression correlated with the levels of platelet bound MIF 
and GREM1 proteins. P-selectin, a known recruitment and aggregation factor of 
platelets, has been found to correlate with the severity of acute coronary 
syndromes in patients with IHD, most probably through plaque disruption, 
rupture and thrombus formation (12, 19, 86). Increased expression of platelet 
glycoprotein VI (GPVI) correlated with increased MIF and GREM1 platelet 
expression. GPVI is a transmembranous glycoprotein that forms a complex with 
the Fc receptor at the platelet surface (111). Fc receptor expression correlates 
with collagen-induced aggregation and has been found increased in diabetics 
(28, 29). GPVI has been implicated in platelet-mediated arterial thrombosis (99), 
whereas it has been shown that platelets of patients with T2DM express GPVI 
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on their surface more than those of nondiabetics (25). The platelet binding of 
PAC-1, another monocolonal antibody that selectively interacts with activated 
GP IIb/IIIa, was also used as a platelet activation marker (86) and we found an 
up-regulation of expression correlates with up-regulated MIF and GREM1 
platelet expression. 
 
Such findings suggest a cross talk between activated leukocytes and platelets 
and regulation of platelet activation through inflammation and thus a role for 
GREM1 and MIF in atherothrombosis and acute myocardial infarctions.  
 
In concordance with findings of previous studies plasma levels of MIF were 
found slightly elevated in patients with diabetes (76, 158), whereas the plasma 
levels of GREM1 in the same patient group were also found slightly elevated. 
When we compared levels of platelet bound MIF and GREM1 in diabetics and 
nondiabetics we found them significantly higher in diabetics in comparison to 
nondiabetics, while a more traditional marker for inflammation CRP, was also 
found increased. These results support the theory of platelet mediated GREM1 
and MIF expression as important mediator in vascular inflammation in diabetics 
and the progression of CAD. Furthermore, levels of MIF and GREM1 expressed 
from platelets showed no correlation with the various therapy schemes, but only 
to the HbA1c levels, suggesting a direct correlation of MIF and GREM1 
expression with the glucose levels and the progression of inflammatory 
mediated atherosclerosis in diabetics.  
 
Only the levels of GREM1 correlated well with the maximum of creatinine 
kinase, while both the levels of GREM1 and MIF correlated with the most 
sensitive marker for cardiac injury at the moment, troponin. The higher the 
troponin levels were the lower the expression of MIF and GREM1 was. In 
patients with ACS expression of MIF and GREM1 was significantly lower than in 
patients with stable CHD. MIF and GREM1 levels also correlated with the 
ejection fraction of patients undergoing a cardiac ventriculography with down-
regulation of MIF and GREM1 expression in patients with a left ventricular 
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dysfunction as consequence of a myocardial infarction.  In those patients the 
plasma levels of GREM1 and MIF were found slightly higher. These findings 
highlight the connection of platelet bound MIF and GREM1 with the settings of 
ACS and the prognostic factors of CHD.  
 
These finding could extend the role of GREM1 and MIF as markers for 
imminent myocardial ischemia in IHD and prognostic markers of the severity 
and the stadium of the disease. It could be suggested that ongoing ischemia 
causes platelets to release MIF and GREM1 produced in platelets to the 
adjacent tissues and into plasma, thus propagating atherothrombotic 
processes, myocardial fibrosis and post-infarction heart failure.   
 
With the results of our current study are taken into account, one could conclude 
that platelets serve as carriers of MIF and GREM1 in patients with coronary 
artery disease and seem to release GREM1 and MIF during ACS. Patients at 
risk for a rapid progression of atherosclerosis, such as diabetic patients or 
patients with a high platelet activation status show a significant up-regulation of 
GREM1 and MIF. GREM1 and MIF might therefore be useful biomarkers in the 
clinical routine to assess individual risk. Future studies including follow-up 
measurements of MIF and GREM1 levels in CAD patients and studies with 
MACE endpoints are warranted to assess MIF and GREM1 as biomarker. 
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5. ZUSAMMENFASSUNG 
 
Die Progression der Atherosklerose ist ein langjähriger Prozess und Diabetes 
mellitus stellt einen der wichtigsten Risikofaktoren der koronaren Herzkrankheit 
dar. Thrombozyten spielen eine wichtige Rolle bei der Hämostase, aber auch 
bei inflammatorischen Prozessen und bei der Atherosklerose sind sie 
wesentlich beteiligt, unter anderem, durch die zahlreiche Zytokine die sie 
beherbergen und die Bildung von Thromben auf rupturierten Plaques, was zum 
akuten Verschluss und damit zum akuten Myokardinfarkt führt. Makrophage 
migration inhibitory factor (MIF) ist ein ubiquitärer Mediator mit 
proinflammatorischer Wirkung. Seine Interaktion mit GREM1 in der 
Atherosklerose in APO-Mäusen wurde durch unsere Gruppe beschrieben und 
die Rolle von GREM1 als endogener Inhibitor von MIF  erläutert. 
Um die Expression, Funktion und Interaktion von MIF und GREM1 in der 
Atherogenese zu analysieren, untersuchten wir in 300 KHK-Patienten die 
Expression von MIF und GREM1 von Thrombozyten mittels Western Blotting 
und Durchflusszytometrie und deren Plasma-Spiegel durch ELISA.  Die MIF 
und GREM1 Expression war unabhängig von Thrombozytenzahl, 
Leukozytenzahl und begleitender medikamentöser Therapie, inklusive 
Thrombozytenaggregationshemmer. Bei Diabetikern waren 
Thrombozytenaktivierungsmarker signifikant höher und korrelierten sich mit der 
thrombozytären Expression von MIF und GREM1. Zudem waren bei 
Diabetikern die MIF- und GREM1-Konzentration im Serum höher und die 
thrombozytenassozierte Expression von MIF und GREM1 korrelierten 
signifikant mit dem HbA1c-Wert, mit dem Troponin und mit der Ejektions-
Fraktion.  
Unsere Ergebnisse lassen darauf schließen, dass Thrombozyten als Quelle von 
MIF und GREM1 dienen, die als Mediatoren der vaskulären Inflammation bei 
Diabetikern agieren. Diese Erkenntnisse bringen wichtige Informationen über 
mögliche Interaktionen von MIF und GREM1 und die damit verbundene 
mögliche Entwicklung spezifischer Inhibitoren, womit neue Therapieansätze in 
der Behandlung der vaskulären Komplikationen des Diabetes mellitus 
geschaffen werden können. 
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